Development of a novel and unique disease-specific treatment for ANCA vasculitis
| Reference number | |
| Coordinator | Bonsai Biotherapeutics AB |
| Funding from Vinnova | SEK 2 912 709 |
| Project duration | April 2023 - January 2026 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
| Call | Swelife and Medtech4Health - Collaborative projects for better health autumn 2022 |
Important results from the project
The project achieved its main objectives by identifying disease-relevant peptides in patients with ANCA-vasculitis and by functionally characterizing autoreactive T cell responses in human samples. Advanced analytical methods, including flow cytometry and cytokine analyses, were established, generating a valuable human dataset that supports further development of the drug candidate TOL3.
Expected long term effects
In the long term, the project is expected to contribute to the development of more precise and disease-specific therapies for ANCA-associated vasculitis. The established methodological platform and insights into human T cell responses may also be applied more broadly in autoimmune disease research and drug development, supporting continued R&D and innovation.
Approach and implementation
The project was carried out through close collaboration between industry, healthcare, academia and bio-data analysis partners. The work focused on the analysis of human samples using advanced techniques for peptide identification, bioinformatics and immunological characterization. The collaboration functioned well and enabled efficient project execution with high-quality data generation.